Paratek Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:PRTK
CUSIP89354M10
Phone617-807-6600
Debt
Debt-to-Equity Ratio0.47
Current Ratio8.06
Quick Ratio8.06
Price-To-Earnings
Trailing P/E Ratio-3.21
Forward P/E Ratio-2.88
P/E GrowthN/A
Sales & Book Value
Annual Sales$12.62 million
Price / Sales26.54
Cash FlowN/A
Price / CashN/A
Book Value$2.65 per share
Price / Book4.00
Profitability
EPS (Most Recent Fiscal Year)($3.30)
Net Income$-89,060,000.00
Net Margins-707.08%
Return on Equity-87.29%
Return on Assets-50.20%
Miscellaneous
Employees83
Outstanding Shares31,600,000
Market Cap$334.92
Paratek Pharmaceuticals (NASDAQ:PRTK) Frequently Asked Questions
What is Paratek Pharmaceuticals' stock symbol?
Paratek Pharmaceuticals trades on the NASDAQ under the ticker symbol "PRTK."
How were Paratek Pharmaceuticals' earnings last quarter?
Paratek Pharmaceuticals Inc (NASDAQ:PRTK) released its quarterly earnings data on Wednesday, May, 9th. The specialty pharmaceutical company reported ($0.91) earnings per share for the quarter, beating analysts' consensus estimates of ($0.94) by $0.03. The specialty pharmaceutical company had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.02 million. Paratek Pharmaceuticals had a negative net margin of 707.08% and a negative return on equity of 87.29%. View Paratek Pharmaceuticals' Earnings History.
What price target have analysts set for PRTK?
7 brokers have issued 1 year price objectives for Paratek Pharmaceuticals' shares. Their forecasts range from $36.00 to $55.00. On average, they expect Paratek Pharmaceuticals' share price to reach $45.00 in the next year. This suggests a possible upside of 324.5% from the stock's current price. View Analyst Ratings for Paratek Pharmaceuticals.
What is the consensus analysts' recommendation for Paratek Pharmaceuticals?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Paratek Pharmaceuticals in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
Who are some of Paratek Pharmaceuticals' key competitors?
Some companies that are related to Paratek Pharmaceuticals include Myovant Sciences (MYOV), Radius Health (RDUS), Uniqure (QURE), Eagle Pharmaceuticals (EGRX), Alder Biopharmaceuticals (ALDR), Zai Lab (ZLAB), Reata Pharmaceuticals (RETA), Retrophin (RTRX), Endocyte (ECYT), Athenex (ATNX), Tricida (TCDA), Esperion Therapeutics (ESPR), Wave Life Sciences (WVE), Intra-Cellular Therapies (ITCI) and Vanda Pharmaceuticals (VNDA).
Who are Paratek Pharmaceuticals' key executives?
Paratek Pharmaceuticals' management team includes the folowing people:
- Mr. Michael F. Bigham, Chairman & CEO (Age 60)
- Dr. Evan Loh, Pres, Chief Medical Officer, COO & Director (Age 59)
- Mr. Douglas W. Pagán, Chief Financial Officer (Age 46)
- Mr. William M. Haskel, Sr. VP, Gen. Counsel & Corp. Sec. (Age 56)
- Mr. Adam Woodrow, Chief Commercial Officer & VP (Age 51)
Has Paratek Pharmaceuticals been receiving favorable news coverage?
Media stories about PRTK stock have trended somewhat positive this week, according to Accern. The research firm ranks the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Paratek Pharmaceuticals earned a news impact score of 0.21 on Accern's scale. They also assigned news headlines about the specialty pharmaceutical company an impact score of 46.12 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future.
How do I buy shares of Paratek Pharmaceuticals?
Shares of PRTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Paratek Pharmaceuticals' stock price today?
One share of PRTK stock can currently be purchased for approximately $10.60.
How big of a company is Paratek Pharmaceuticals?
Paratek Pharmaceuticals has a market capitalization of $334.92 million and generates $12.62 million in revenue each year. The specialty pharmaceutical company earns $-89,060,000.00 in net income (profit) each year or ($3.30) on an earnings per share basis. Paratek Pharmaceuticals employs 83 workers across the globe.
How can I contact Paratek Pharmaceuticals?
Paratek Pharmaceuticals' mailing address is 75 PARK PLAZA, BOSTON MA, 02116. The specialty pharmaceutical company can be reached via phone at 617-807-6600 or via email at [email protected]
MarketBeat Community Rating for Paratek Pharmaceuticals (NASDAQ PRTK)
MarketBeat's community ratings are surveys of what our community members think about Paratek Pharmaceuticals and other stocks. Vote "Outperform" if you believe PRTK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRTK will underperform the S&P 500 over the long term. You may vote once every thirty days.
